Correction: Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study

• Charles Ferte,
• Benjamin Frey,
• Markus Hecht,
• Rainer Fietkau,
• Nora Sundahl,
• Florian Putz,
• Andrea Lancia,
• Angela Rouyar,
• Marina Milic,
• Alexandre Carré,
• Enzo Battistella,
• Emilie Alvarez Andres,
• Stéphane Niyoteka,
• Edouard Romano,
• Jérôme Durand-Labrunie,
• Sophie Bockel,
• Rastilav Bahleda,
• Charlotte Robert,
• Celine Boutros,
• Maria Vakalopoulou,
• Nikos Paragios,
• Piet Ost,
• Udo Gaipl

Affiliations

Charles Ferte

Aff2 grid.418152.bMedImmune Gaithersburg MD USA

Benjamin Frey

Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Bayern, Germany

Markus Hecht

Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Bayern, Germany

Rainer Fietkau

Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Bayern, Germany

Nora Sundahl

Department of Radiation Oncology, University Hospital Ghent, Gent, Oost-Vlaanderen, Belgium

Florian Putz

Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

Andrea Lancia

Department of Radiation Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Lombardia, Italy

Angela Rouyar

Institut Gustave Roussy, Inserm, Radiothérapie Moléculaire et Innovation Thérapeutique, Paris-Saclay University, Villejuif, Île-de-France, France

Marina Milic

Institut Gustave Roussy, Inserm, Radiothérapie Moléculaire et Innovation Thérapeutique, Paris-Saclay University, Villejuif, Île-de-France, France

Alexandre Carré

Department of Radiation Oncology, Gustave Roussy, Villejuif, Île-de-France, France

Enzo Battistella

Institut Gustave Roussy, Inserm, Radiothérapie Moléculaire et Innovation Thérapeutique, Paris-Saclay University, Villejuif, Île-de-France, France

Emilie Alvarez Andres

Institut Gustave Roussy, Inserm, Radiothérapie Moléculaire et Innovation Thérapeutique, Paris-Saclay University, Villejuif, Île-de-France, France

Stéphane Niyoteka

Institut Gustave Roussy, Inserm, Radiothérapie Moléculaire et Innovation Thérapeutique, Paris-Saclay University, Villejuif, Île-de-France, France

Edouard Romano

Department of Radiation Oncology, Gustave Roussy, Villejuif, Île-de-France, France

Jérôme Durand-Labrunie

Department of Radiation Oncology, Gustave Roussy, Villejuif, Île-de-France, France

Sophie Bockel

Department of Radiation Oncology, Gustave Roussy, Villejuif, Île-de-France, France

Rastilav Bahleda

Drug Development Department, Gustave Roussy, Villejuif, Île-de-France, France

Charlotte Robert

Department of Radiation Oncology, Gustave Roussy, Villejuif, Île-de-France, France

Celine Boutros

Departement of Medicine, Gustave Roussy, Villejuif, Île-de-France, France

Maria Vakalopoulou

CentraleSupélec, Gif-sur-Yvette, Île-de-France, France

Nikos Paragios

TheraPanacea, Paris, France

Piet Ost

Department of Radiation Oncology, University Hospital Ghent, Gent, Oost-Vlaanderen, Belgium

Udo Gaipl

Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany